964 results match your criteria Current Treatment Options in Oncology[Journal]


Treatment of Radiation-Induced Cognitive Decline in Adult Brain Tumor Patients.

Curr Treat Options Oncol 2019 Apr 8;20(5):42. Epub 2019 Apr 8.

Oncology, Medical Neuro-Oncology and Neuro-Oncology Research Program, Wake Forest Baptist Comprehensive Cancer Center, Medical Center Boulevard, Winston-Salem, NC, 27157-1082, USA.

Opinion Statement: Patients with either primary or metastatic brain tumors quite often have cognitive impairment. Maintaining cognitive function is important to brain tumor patients and a decline in cognitive function is generally accompanied by a decline in functional independence and performance status. Cognitive decline can be a result of tumor progression, depression/anxiety, fatigue/sleep dysfunction, or the treatments they have received. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0641-6DOI Listing

The Changing Landscape of Management of Metastatic Renal Cell Carcinoma: Current Treatment Options and Future Directions.

Curr Treat Options Oncol 2019 Apr 1;20(5):41. Epub 2019 Apr 1.

Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, Duarte, CA, 91010, USA.

Opinion Statement: For the practicing clinician, the dilemma becomes how most appropriate to sequence the aforementioned regimens. It is challenging to be dogmatic, as there are no comparative studies juxtaposing novel front-line options directly-all of the available studies utilize a comparator arm of sunitinib. With this in mind, the selection of front-line therapy with a patient with mRCC should involve a thorough discussion of both efficacy and safety of available options. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0638-1DOI Listing
April 2019
1 Read

Optimal Management of Upper Tract Urothelial Carcinoma: an Unmet Need.

Curr Treat Options Oncol 2019 Apr 1;20(5):40. Epub 2019 Apr 1.

Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.

Opinion Statement: Upper tract urothelial carcinoma (UTUC) is a rare genitourinary entity of the renal pelvis and the ureter characterized by a more aggressive disease phenotype when compared with urothelial carcinoma of the bladder (UCB) with more than half of UTUC cases presenting with invasive disease at diagnosis compared to 20% for bladder tumors. There is growing evidence suggesting that its distinct natural history from that of bladder cancer can be related to several genetic and epigenetic differences. Treatment of low-risk disease consists of kidney-sparing surgeries such as ureteroscopic and percutaneous treatments, segmental ureterectomy, and adjuvant topical and intracavitary chemo-immunotherapies. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-019-0637-2
Publisher Site
http://dx.doi.org/10.1007/s11864-019-0637-2DOI Listing
April 2019
3 Reads

Survivorship Guidance for Patients with Colorectal Cancer.

Curr Treat Options Oncol 2019 Apr 1;20(5):38. Epub 2019 Apr 1.

Northwestern University Feinberg School of Medicine, 676 N Saint Clair, Suite 850, Chicago, IL, 60611, USA.

Opinion Statement: Effective therapy for treatment of colorectal cancer includes comprehensive and evidence-based therapies that may include a combination of surgery, chemotherapy, targeted therapy, and/or radiation. However, in order to provide patients with the highest quality of care, providers must consider all aspects of survivorship care including: surveillance for recurrence/second primaries, genetic counseling, psychosocial/physical late effects of cancer and its therapies, and preventative lifestyle strategies. Health systems, providers, and researchers need to identify systematic methods of addressing the unique needs of the survivorship population that include multidisciplinary teams including supportive oncology (i. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0635-4DOI Listing
April 2019
2 Reads

Opioid Prescribing in an Opioid Crisis: What Basic Skills Should an Oncologist Have Regarding Opioid Therapy?

Curr Treat Options Oncol 2019 Apr 1;20(5):39. Epub 2019 Apr 1.

Department of Palliative, Rehabilitation, & Integrative Medicine, The University of Texas MD Anderson Cancer, Unit 1414, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.

Opinion Statement: Although clinical evidence supports the use of opioids for cancer-related pain, doing so amidst the current opioid crisis remains a challenge. A proportion of opioid-related deaths in the USA are attributable to prescription opioids, which implicates health care providers as one of the major contributors. It is therefore even more important now for all clinicians to follow safe and effective opioid prescribing practices. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0636-3DOI Listing
April 2019
1 Read

Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review.

Curr Treat Options Oncol 2019 Apr 1;20(5):37. Epub 2019 Apr 1.

Department of Research, Institut Jules Bordet; Université Libre de Bruxelles, Boulevard de Waterloo, 121 1000, Brussels, Belgium.

Opinion Statement: Antibody-drug conjugates are an elegant approach to cancer treatment that couples the specificity of monoclonal antibodies to the cytotoxicity of classic chemotherapy agents, permitting, at least in theory, increased activity and reduced toxicity. In breast cancer, the early success of trastuzumab-emtansine (T-DM1) in the HER2-positive metastatic setting led to great hopes, later dashed by results in the early setting (KRISTINE trial) and in combination with pertuzumab (MARIANNE trial). Parallel to this, development of ADCs in breast cancer has suffered other setbacks, including the recent failure of other agents (MM-302) as well as the suspension of a few programs (XMT-1522, ADCT-502) with the overall effect of dampening the impetus of this concept and halting/delaying the progress of drugs associated with it, particularly when immunotherapy is at the center of so many efforts. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-019-0633-6
Publisher Site
http://dx.doi.org/10.1007/s11864-019-0633-6DOI Listing
April 2019
7 Reads

Surgical Options for Locally Advanced Oropharyngeal Cancer.

Curr Treat Options Oncol 2019 Apr 1;20(5):36. Epub 2019 Apr 1.

Department of Otolaryngology-Head and Neck Surgery, University of Washington, 1959 NE Pacific St., Campus Box 356515, Seattle, WA, 98195, USA.

Opinion Statement: Oropharyngeal squamous cell carcinoma (OPSCC) incidence rates have been steadily increasing over the past several decades, and this has been largely attributed to human papillomavirus (HPV)-related OPSCC. The rise of HPV-related OPSCC and the observed distinct survival advantage it offers compared to HPV-unrelated OPSCC have resulted in the development of a new staging system specifically for OPSCC in the eighth edition of the AJCC Staging Manual for head and neck cancer. The observations on HPV-related OPSCC and its prognostic implications have coincided with increasing utilization of transoral surgical approaches to oropharyngeal tumors, such as transoral laser microsurgery (TLM) and transoral robotic surgery (TORS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0621-xDOI Listing
April 2019
1 Read

Checkpoint Blockade Strategies in the Treatment of Breast Cancer: Where We Are and Where We Are Heading.

Curr Treat Options Oncol 2019 Mar 28;20(4):35. Epub 2019 Mar 28.

Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Opinion Statement: Immunotherapy has become one of the greatest advances in medical oncology over the last century; however, the optimal application for the treatment of breast cancer remains an active area of investigation. Modern immunotherapy strategies augment the immune system and ideally, permit durable tumor-specific immune memory. In fact, several monoclonal antibodies that mediate the immune checkpoint receptors have provided the most clinically meaningful improvement for breast cancer patients to date, particularly for the triple negative subtype. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-019-0634-5
Publisher Site
http://dx.doi.org/10.1007/s11864-019-0634-5DOI Listing
March 2019
9 Reads

Symptoms of and Palliative Treatment for Unresectable Skin Cancer.

Curr Treat Options Oncol 2019 Mar 27;20(4):34. Epub 2019 Mar 27.

Division of Dermatology, Department of Medicine of Sensory and Motor Organs, Faculty of Medicine, Tottori University, 36-1, Nishicho, Yonago, Tottori, 683-8503, Japan.

Opinion Statement: The symptom prevalence in patients with advanced cancer depends on the type of primary cancer, and the palliative treatment varies according to the nature of the primary cancer. Palliative treatment for unresectable skin cancer has not been fully discussed. Patients with unresectable skin cancer sometimes show the primary lesion in the skin and metastases to the lung, skin, liver, and bone. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0626-5DOI Listing
March 2019
2 Reads

The Need to Prioritize and Re-prioritize Palliative Care Options: Smoking Cessation as a Case-in-Point.

Curr Treat Options Oncol 2019 Mar 22;20(4):33. Epub 2019 Mar 22.

Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.

Opinion Statement: Palliative care in cancer patients requires a continuous reprioritization of effort. This review describes the need for this reprioritization and uses smoking cessation as a case-in-point. The treatment of patients with metastatic non-small cell lung cancer has changed dramatically in the past few years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0632-7DOI Listing

The Role of Surgery in Management of Locally Advanced Non-Small Cell Lung Cancer.

Curr Treat Options Oncol 2019 Mar 14;20(4):27. Epub 2019 Mar 14.

Section of Thoracic Surgery, Department of Surgery, The University of Chicago Medicine and Biological Sciences, 5841 S. Maryland Ave, Chicago, IL, USA.

Opinion Statement: Patients with locally advanced non-small cell lung cancer (NSCLC) are treated for cure, but treatment decisions are not straightforward. Chemotherapy is essential due to the high risk of systemic relapse, but local therapy is also required for cure. In the small subset of stage III patients with N0 or N1 disease, surgery is typically the initial therapy and extended resections are frequent. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0624-7DOI Listing
March 2019
1 Read

Immunotherapy Approaches Beyond PD-1 Inhibition: the Future of Cellular Therapy for Head and Neck Squamous Cell Carcinoma.

Curr Treat Options Oncol 2019 Mar 14;20(4):31. Epub 2019 Mar 14.

Division of Medical Oncology, Department of Medicine, University of Washington, 825 Eastlake Ave East, Mail Stop K2-231, Seattle, WA, 98109, USA.

Opinion Statement: In a span of a few years, the surprising early successes of programmed cell death 1 (PD-1) inhibitors across a vast range of tumor types have transformed our understanding of cancer immunogenicity and provided proof of principle that T cells, if manipulated, can mediate meaningful tumor regression. In head and neck cancer, only a minority of patients respond to PD-1 therapy, but these small outcomes have fueled the enthusiasm for the next generation of immunotherapy-adoptive cell therapy-which employs recent advances in genetic engineering and cell culturing methods to generate T cells with enhanced anti-tumor efficacy for infusion back into the patient. Head and neck cancer is comprised of biologically distinct cancers, HPV-positive and HPV-negative, and the clinical responses to PD-1 inhibitors in both HPV-positive and HPV-negative head and neck patients have showcased better than any other cancer type that there are distinct pathways to immunogenicity that may lend themselves to different therapeutic approaches. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0630-9DOI Listing
March 2019
4 Reads

Contemporary Treatment of Locally Advanced Oral Cancer.

Authors:
David Kim Ryan Li

Curr Treat Options Oncol 2019 Mar 14;20(4):32. Epub 2019 Mar 14.

Department of Otolaryngology-Head and Neck Surgery, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, PV01, Portland, OR, 97239, USA.

Opinion Statement: At our institution, locally advanced oral cancer is most commonly treated with surgical resection, immediate reconstruction, and adjuvant radiotherapy with or without concurrent systemic therapy depending on final surgical pathologic analysis. There are patients with markedly advanced local or regional disease who unfortunately will have a low probability of cure. We counsel these patients on induction chemotherapy, emphasizing that this is unlikely to result in a smaller volume of surgical resection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0631-8DOI Listing
March 2019
1 Read

Systemic Immunotherapy for Advanced Cutaneous Squamous Cell Carcinoma.

Curr Treat Options Oncol 2019 Mar 14;20(4):30. Epub 2019 Mar 14.

Department of Dermatology, Saitama Medical University, Morohongo 38, Moroyama-machi, Iruma-gun, Saitama, 350-0495, Japan.

Opinion Statement: Advanced (i.e., unresectable) cutaneous squamous cell carcinoma (cSCC) is a rare condition with a dismal prognosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0629-2DOI Listing
March 2019
4 Reads

Current Update on the Molecular Biology of Cutaneous Sarcoma: Dermatofibrosarcoma Protuberans.

Curr Treat Options Oncol 2019 Mar 14;20(4):29. Epub 2019 Mar 14.

Department of Anatomic Pathology, Graduate School of Medicine Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.

Opinion Statement: Cutaneous sarcoma is a group of malignant mesenchymal tumors primarily involving the dermis, and it is characterized by extreme clinicopathological heterogeneity. Although its occurrence rate is rare, dermatofibrosarcoma protuberans (DFSP) is one of the most common types of dermal sarcoma. DFSP grows slowly and tends to relapse locally after inadequate resection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0628-3DOI Listing
March 2019
1 Read

Role of Bisphosphonates in Breast Cancer Therapy.

Curr Treat Options Oncol 2019 Mar 14;20(4):26. Epub 2019 Mar 14.

Division of Medical Oncology, University of Toronto and Princess Margaret Cancer Centre, 700 University Ave, 7-721, Toronto, ON, M5G 2M9, Canada.

Opinion statement Bisphosphonates are utilized routinely in breast cancer. In metastatic disease with bone involvement, bisphosphonates prevent or delay skeletal-related events and can improve pain control. Different agents have shown benefit compared with placebo or no treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0623-8DOI Listing
March 2019
7 Reads

Clinical Use of Measurable Residual Disease in Acute Myeloid Leukemia.

Curr Treat Options Oncol 2019 Mar 14;20(4):28. Epub 2019 Mar 14.

Department of Hematology, Aarhus University Hospital, Palle-Juul Jensens Boulevard 99, DK-8200, Aarhus N, Denmark.

Opinion Statement: Treatment of acute myeloid leukemia (AML) remains a high-risk venture for the patient suffering from the disease. There is a real risk of succumbing to the treatment rather than the disease, and even so, cure is much less than certain. Since the establishment of complete remission as a prerequisite for cure in the 1960s, a number of years passed before advanced techniques for detecting minute amounts of disease matured sufficiently for clinical implementation. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-019-0627-4
Publisher Site
http://dx.doi.org/10.1007/s11864-019-0627-4DOI Listing
March 2019
8 Reads

Controversies in the Therapy of Low-Grade Gliomas.

Curr Treat Options Oncol 2019 Mar 14;20(4):25. Epub 2019 Mar 14.

Department of Medical Oncology, Mayo Clinic Rochester, 200 1st St SW, Rochester, MN, 55905, USA.

Opinion Statement: In the context of the new WHO classification system, all low-grade gliomas must have an IDH mutation, with or without 1p/19q codeletion. Upon discovery of the tumor, maximal safe surgical resection is the most appropriate first step due to the current inability to differentiate between IDH mutant and IDH wild-type tumors by imaging alone. In the postoperative setting, based on the synthesis and interpretation of the available data, we recommend utilizing conventional radiation therapy and PCV in all high-risk-low-grade gliomas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0625-6DOI Listing
March 2019
3 Reads

Current State of Immunotherapy for Treatment of Glioblastoma.

Curr Treat Options Oncol 2019 Feb 21;20(3):24. Epub 2019 Feb 21.

Department of Neurology, Stanford University, Stanford, CA, USA.

Opinion Statement: At this time, there are no FDA-approved immune therapies for glioblastoma (GBM) despite many unique therapies currently in clinical trials. GBM is a highly immunosuppressive tumor and there are limitations to a safe immune response in the central nervous system. To date, there have been several failures of phase 3 immune therapy clinical trials in GBM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0619-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394457PMC
February 2019
1 Read

Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really "Raising the Bar?"

Curr Treat Options Oncol 2019 Feb 21;20(3):23. Epub 2019 Feb 21.

UOC di Oncologia Medica - Università Cattolica del Sacro Cuore - Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Francesco Vito 1, 00168, Rome, Italy.

Opinion Statement: Unresectable or relapsed malignant pleural mesothelioma (MPM) has dismal prognosis. First-line combination therapy with pemetrexed and a platinum analog allows a modest survival benefit, while no clear therapeutic options exist for the second-line therapy. In this setting, pemetrexed seems to be the most active drug; however, the inclusion in front-line treatment limits its use in further lines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0616-7DOI Listing
February 2019
2 Reads

The Potential of Targeting P53 and HSP90 Overcoming Acquired MAPKi-Resistant Melanoma.

Curr Treat Options Oncol 2019 Feb 18;20(3):22. Epub 2019 Feb 18.

National Institute of Cancer Research, National Health Research Institutes, No.367, Sheng-Li Rd., North Dist., 70456, Tainan, Taiwan.

Opinion Statement: Melanoma is the deadliest form of skin cancer worldwide. The rising melanoma incidence and mortality, along with its high propensity for metastasis highlights the urgency to identify more effective therapeutic targets. Approximately, one half of advanced melanoma bears a mutation in the BRAF gene that makes BRAF as an important therapeutic target. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0622-9DOI Listing
February 2019
1 Read

The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer.

Curr Treat Options Oncol 2019 Feb 18;20(3):21. Epub 2019 Feb 18.

Princess Margaret Cancer Centre, Division of Medical Oncology, University of Toronto, 7-913 700 University Avenue, Toronto, ON, M5G 1Z5, Canada.

Opinion Statement: The treatment of advanced non-small cell lung cancer (NSCLC) has evolved to include targeted therapy, immunotherapy as well as chemotherapy for selected patients in the first-line setting. Angiogenesis inhibitors have been used in combination with chemotherapy in the first-line and maintenance settings providing improved progression-free survival (PFS) and objective response rate (ORR), as well as overall survival (OS) in selected studies. Biologic rationale exists for combining anti-angiogenic agents with immunotherapy and targeted kinase inhibitors (TKIs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0617-6DOI Listing
February 2019
8 Reads

Postoperative Treatment of Oropharyngeal Cancer in the Era of Human Papillomavirus.

Curr Treat Options Oncol 2019 Feb 15;20(3):20. Epub 2019 Feb 15.

Department of Head and Neck Oncologic Surgery, Head and Neck Institute, Cleveland Clinic, 9500 Euclid Avenue, A-71, Cleveland, OH, 44195, USA.

Opinion Statement: Despite an overall decline in the incidence of tobacco-related cancers, human papillomavirus (HPV)-related head and neck squamous cell carcinoma (HNSCC) of the oropharynx is on the rise. The prognosis of HPV-related oropharynx cancer (HPV-OPC) is generally favorable even in locoregionally advanced disease, and a variety of treatment options are available. Though the primary treatment modality of choice remains definitive radiation (RT), surgical resection followed by appropriate adjuvant therapy remains an option, especially in those patients who may not be favorable candidates for definitive radiotherapy, particularly when concurrent chemotherapy is warranted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0620-yDOI Listing
February 2019
1 Read

Current Treatment Options for Breast Cancer Brain Metastases.

Curr Treat Options Oncol 2019 Feb 15;20(3):19. Epub 2019 Feb 15.

Department of Medicine, Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological Institute, Cleveland Clinic, 9500 Euclid Ave, S73, Cleveland, OH, 44195, USA.

Opinion Statement: In the past, the standard of care for treatment of BM was whole brain radiation therapy (WBRT), stereotactic radiosurgery (SRS), and surgery. There has been a greater role for medical therapies in the last two decades due to the discovery of driver mutations and corresponding targeted therapies. These innovations have dramatically altered the approach to treating these patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0618-5DOI Listing
February 2019
3 Reads

Use of Immune Checkpoint Inhibitors in Mesothelioma.

Curr Treat Options Oncol 2019 Feb 14;20(2):18. Epub 2019 Feb 14.

Department of Thoracic/Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd. Unit 432, Houston, TX, 77030, USA.

Opinion Statement: Recent advances in immunology have extended into the mesothelioma field. To date, only Japan has given regulatory approval to salvage nivolumab in chemo-refractory mesothelioma patients. The USA has included in the NCCN guidelines that pembrolizumab (in programmed death ligand 1 (PD-L1) immunohistochemistry (IHC)-positive patients) and nivolumab with or without ipilimumab (whatever the PD-L1 status is) are accepted salvage therapies. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-019-0613-x
Publisher Site
http://dx.doi.org/10.1007/s11864-019-0613-xDOI Listing
February 2019
7 Reads

Updates on Minimally Invasive Surgery in Non-Small Cell Lung Cancer.

Authors:
Norihiko Ikeda

Curr Treat Options Oncol 2019 Feb 11;20(2):16. Epub 2019 Feb 11.

Department of Thoracic Surgery, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.

Opinion Statement: Video-assisted thoracic surgery (VATS) has become widely used since the 1990s and has become a standard treatment approach mainly for early-stage non-small cell lung cancer. The few randomized controlled trials providing evidence of the effectiveness of VATS lobectomy at present are supported by a large number of propensity-matched studies, several high-quality meta-analyses, and outcome studies. These studies provide comprehensive data demonstrating the lower morbidity, shorter chest tube duration, and shorter hospital stay of VATS than thoracotomy during the postoperative course. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0614-9DOI Listing
February 2019
1 Read

Prognostic Significance of Complex Karyotypes in Acute Myeloid Leukemia.

Curr Treat Options Oncol 2019 Feb 11;20(2):15. Epub 2019 Feb 11.

Department of Pathology, University of Chicago, Chicago, IL, USA.

Opinion Statement: Acute myeloid leukemia (AML) patients with a complex karyotype (CK-AML) show at least 3 unrelated clonal cytogenetic abnormalities with notoriously poor outcome. Such cases fall into either AML with myelodysplasia-related changes or therapy-related AML in the current World Health Organization classification of AML. Allogeneic stem cell transplantation is one of the only treatment modalities that can provide a long-term survival benefit and is recommended as a consolidative treatment in patients who are able to achieve complete remission. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0612-yDOI Listing
February 2019
7 Reads

Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer.

Curr Treat Options Oncol 2019 Feb 11;20(2):12. Epub 2019 Feb 11.

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, DANA 1230, Boston, MA, 02215, USA.

Opinion Statement: Cisplatin has been established as an important agent in the neoadjuvant setting prior to radical cystectomy (RC) surgery for muscle-invasive urothelial cancer (MIUC) as well as in the unresectable or metastatic urothelial carcinoma (mUC) setting. Unfortunately, many patients in practice are felt to be "cisplatin-ineligible." Thus, it is vital that we develop treatment approaches and novel therapeutics for this population. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-019-0609-6
Publisher Site
http://dx.doi.org/10.1007/s11864-019-0609-6DOI Listing
February 2019
15 Reads

Innovating Cancer Care Delivery: the Example of the 4R Oncology Model for Colorectal Cancer Patients.

Curr Treat Options Oncol 2019 Feb 11;20(2):11. Epub 2019 Feb 11.

Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Opinion Statement: Care delivery innovation is necessary to address the growing complexity of cancer care across specialties and integrate new diagnostics, treatments, and services into care delivery. Informed by Cancer Care Delivery Research (CCDR), multilevel intervention research, and other disciplines, this article describes the 4-step cancer care delivery innovation cycle. The cycle guides collaborative efforts of cancer clinicians, researchers, patients, and other stakeholders to systematically define care delivery problems and formulate, test, and implement care innovations to effectively address problems. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-019-0608-7
Publisher Site
http://dx.doi.org/10.1007/s11864-019-0608-7DOI Listing
February 2019
7 Reads

Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction.

Curr Treat Options Oncol 2019 Feb 11;20(2):14. Epub 2019 Feb 11.

Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.

Opinion Statement: Nonmetastatic castration-resistant prostate cancer (nmCRPC) comprises a relatively narrow niche of advanced prostate cancer, but the treatment landscape for men with nmCRPC has drastically changed over the past year. Prior to the SPARTAN and PROSPER trials, men with nmCRPC were commonly treated with first-generation androgen receptor antagonists, such as bicalutamide or flutamide, or with estrogens or ketoconazole, none of which were associated with any proven survival benefit. The SPARTAN trial evaluated apalutamide versus placebo for men with nmCRPC and found that apalutamide significantly improved metastasis-free survival (MFS), the primary endpoint of this trial. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0611-zDOI Listing
February 2019
2 Reads

Palliative Cancer Care in the Outpatient Setting: Which Model Works Best?

Authors:
David Hui

Curr Treat Options Oncol 2019 Feb 11;20(2):17. Epub 2019 Feb 11.

Department of Palliative Care, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Unit 1414 - 1515 Holcombe Blvd., Houston, TX, 77030, USA.

Opinion Statement: Multiple randomized controlled trials have underscored the importance of timely referral to palliative care for patients with advanced cancer. Outpatient palliative care can facilitate timely referral and is increasingly available in many cancer centers. The key question is which model of outpatient palliative care is optimal. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0615-8DOI Listing
February 2019
3 Reads

Diagnosis and Management of Basal Cell Carcinoma.

Authors:
Keiji Tanese

Curr Treat Options Oncol 2019 Feb 11;20(2):13. Epub 2019 Feb 11.

Department of Dermatology, Keio University School of Medicine, Shinanomachi 35, Shinjuku, Tokyo, 160-8582, Japan.

Opinion Statement: Basal cell carcinomas (BCCs) are common skin cancers that tend to appear on sun-exposed skin. Pathobiologically, activation of the Hedgehog signaling pathway characterizes the majority of cases. In general, BCCs are slow-growing and rarely metastasize. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-019-0610-0
Publisher Site
http://dx.doi.org/10.1007/s11864-019-0610-0DOI Listing
February 2019
10 Reads

Guidelines for Treatment and Monitoring of Adult Survivors of Pediatric Brain Tumors.

Curr Treat Options Oncol 2019 Feb 9;20(1):10. Epub 2019 Feb 9.

Pediatric Endocrinology, Emory Children's Center/Emory Pediatric Institute, 2015 Uppergate Drive, Room 232, Atlanta, GA, 30322, USA.

Opinion Statement: Pathologies of pediatric brain tumors are more varied than those diagnosed in adults and survival outcomes more optimistic. Therapies for pediatric brain tumors are also diverse and treatment options are expanding. The growing number of adult survivors of childhood brain tumors is quite diverse. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0602-0DOI Listing
February 2019
1 Read

Blastic Plasmacytoid Dendritic Cell Neoplasm.

Curr Treat Options Oncol 2019 Feb 4;20(1). Epub 2019 Feb 4.

Department of Hematology and Medical Oncology, Moffitt Cancer Center/University of South Florida, 12902 USF Magnolia Dr, Tampa, FL, 33612, USA.

Opinion Statement: While there is a high initial response rate with standard chemotherapeutic regimens for blastic plasmacytoid dendritic cell neoplasm (BPDCN), the responses are typically not durable and this remains a very aggressive disease with generally poor outcomes. For this reason, the standard approach for eligible patients has been high-dose induction chemotherapy preferably with acute lymphoblastic leukemia (ALL)-based regimens followed by consolidation with allogeneic hematopoietic stem cell transplantation (alloHSCT). Unfortunately, many patients with this disease are elderly and/or frail and cannot tolerate this therapy, and the low-dose regimens being used in this population are generally not as effective. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-019-0605-x
Publisher Site
http://dx.doi.org/10.1007/s11864-019-0605-xDOI Listing
February 2019
8 Reads

The Optimal Duration of Adjuvant Therapy for Stage III Colon Cancer: the European Perspective.

Curr Treat Options Oncol 2019 Jan 26;20(1). Epub 2019 Jan 26.

Policlinico San Martino IRCCS, Largo R. Benzi 10, 16132, Genoa, Italy.

Opinion Statement: The International Duration Evaluation of Adjuvant Therapy (IDEA) collaboration was created to pool data from different studies worldwide in order to assess whether a shorter duration of adjuvant treatment in colon cancer could maintain the expected benefit while reducing toxicity. The results of the IDEA trials were clinically relevant. They confirmed a two- to sixfold reduction in neurotoxicity for the shorter duration across trials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0600-2DOI Listing
January 2019

Targeted Therapy and Immunotherapy for Melanoma in Japan.

Curr Treat Options Oncol 2019 Jan 24;20(1). Epub 2019 Jan 24.

Department of Dermatologic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

Opinion Statement: Melanoma has several clinically and pathologically distinguishable subtypes, which also differ genetically. Mutation patterns vary among different melanoma subtypes, and efficacy of immune-checkpoint inhibitors differs depending on the subtype of melanoma. In spite of the recent revolution of systemic therapies for advanced melanoma, access to innovative agents is still restricted in many countries. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-019-0607-8
Publisher Site
http://dx.doi.org/10.1007/s11864-019-0607-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344396PMC
January 2019
17 Reads

First-Line Therapy for Metastatic Soft Tissue Sarcoma.

Curr Treat Options Oncol 2019 Jan 24;20(1). Epub 2019 Jan 24.

Hematology and Oncology, Mayo Clinic, 5881 E Mayo Blvd., Phoenix, AZ, 85054, USA.

Opinion Statement: Soft tissue sarcomas are rare cancers with an expected incidence of about 14,000 new cases in 2018, and account for less than 1% of all cancers. It includes in excess of 75 heterogeneous subtypes with varying biology, molecular aberrations, and variable response to treatment. Because of the rarity of these tumors and the many different subtypes, there is no large-scale data to guide treatment, and hence the need for a multidisciplinary individualized approach to treatment, preferably at a high-volume tertiary referral center. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0606-9DOI Listing
January 2019
1 Read

New Concepts of Treatment for Patients with Myelofibrosis.

Curr Treat Options Oncol 2019 Jan 24;20(1). Epub 2019 Jan 24.

Department of Leukemia, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX, 77030, USA.

Opinion Statement: Seven years after the approval of the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib, it remains the only drug licensed for the treatment of myelofibrosis. Patients who discontinue ruxolitinib have a dismal outcome, and this is, therefore, an area of significant unmet need. Given the central role that JAK-signal transducer and activator of transcription (STAT) activation plays in disease pathogenesis, there have been many other JAK inhibitors tested, but most have been abandoned, for a variety of reasons. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0604-yDOI Listing
January 2019
6 Reads

Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

Curr Treat Options Oncol 2019 Jan 24;20(1). Epub 2019 Jan 24.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit 0428, Houston, TX, 77030, USA.

Opinion Statement: With the introduction of tyrosine kinase inhibitors (TKIs) in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), the prognosis of patients has improved dramatically. Currently, the standard of care in the frontline setting for fit patients is TKI in combination with chemotherapy. Age-adjusted chemotherapy or corticosteroids alone have been used with TKIs in elderly patients with comorbidities with modest long-term benefit. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-019-0603-z
Publisher Site
http://dx.doi.org/10.1007/s11864-019-0603-zDOI Listing
January 2019
13 Reads

Therapeutic Intensification and Induction Chemotherapy for High-Risk Locally Advanced Squamous Cell Carcinoma.

Curr Treat Options Oncol 2019 Jan 11;20(2). Epub 2019 Jan 11.

Medical Oncology Department, Ospedale dell'Angelo, Venice, Italy.

Opinion Statement: The treatment of HNSCC has rapidly evolved over the past 30 years and multidisciplinary management is required, especially for locally advanced disease (LAHNSCC). Concomitant chemoradiation (cCRT) is the standard of care and cetuximab/RT (CET/RT) is an alternative treatment option, especially for patients unfit for concurrent cisplatin. Several intensification strategies have been explored to improve the outcome of the concomitant treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0599-4DOI Listing
January 2019
5 Reads

Systemic Therapy for Advanced Hepatocellular Carcinoma in an Evolving Landscape.

Curr Treat Options Oncol 2019 Jan 11;20(2). Epub 2019 Jan 11.

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Opinion Statement: Globally, hepatocellular carcinoma (HCC) is a leading cause of cancer-related death and a malignancy with rising incidence. After sorafenib remaining the one and only FDA-approved therapy for the disease for many years, the past 2 years has seen the landscape of available treatments change dramatically. Multiple multi-targeted tyrosine kinases (TKIs) have demonstrated success and garnered FDA approval both in the first- (lenvatinib) and second-line (regorafenib) settings. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-019-0601-1
Publisher Site
http://dx.doi.org/10.1007/s11864-019-0601-1DOI Listing
January 2019
17 Reads

Immunotherapy Advances in Urothelial Carcinoma.

Curr Treat Options Oncol 2018 Dec 15;19(12):79. Epub 2018 Dec 15.

Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.

Opinion Statement: Checkpoint inhibitors have monumentally transformed the treatment of metastatic urothelial carcinoma. While the efficacy and safety of the different agents are similar in platinum-refractory metastatic urothelial carcinoma, pembrolizumab is the only agent that was superior to chemotherapy in a randomized phase III trial. Pembrolizumab and atezolizumab are also approved as first-line therapies in cisplatin-ineligible metastatic urothelial carcinoma. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-018-0598-x
Publisher Site
http://dx.doi.org/10.1007/s11864-018-0598-xDOI Listing
December 2018
18 Reads

Is There Value in Molecular Profiling of Soft-Tissue Sarcoma?

Authors:
Antoine Italiano

Curr Treat Options Oncol 2018 Dec 7;19(12):78. Epub 2018 Dec 7.

Department of Medical Oncology, Institut Bergonié, 229 Cours de L'Argonne, 33076, Bordeaux, France.

Opinion Statement: Soft-tissue sarcomas represent a heterogeneous group of diseases accounting for up to 1% of cancer in adults and 15% of cancer in children. Introduction of next-generation sequencing (NGS) technologies has allowed to gain additional insight into the genetic diversity and complexity of sarcomas, including the potential therapeutic implications of some genetic alterations.Two large studies have investigated the role of targeted NGS to identify actionable mutations in patients with soft-tissue sarcomas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-018-0589-yDOI Listing
December 2018
1 Read

Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.

Curr Treat Options Oncol 2018 Nov 15;19(12). Epub 2018 Nov 15.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, 1155 Herman Pressler Dr. CPB 6.3279, Houston, TX, 77030, USA.

Opinion Statement: Use of poly(ADP-ribose) polymerase (PARP) inhibitors has greatly increased over the past 5 years. With several new Food and Drug Administration (FDA) approvals, three PARP inhibitors have entered into standard of care treatment for epithelial ovarian cancer (including ovarian, fallopian tube, and primary peritoneal cancer). Olaparib and rucaparib currently have indications for treatment of recurrent BRCA mutant ovarian cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-018-0572-7DOI Listing
November 2018
5 Reads

Capecitabine Versus Continuous Infusion Fluorouracil for the Treatment of Advanced or Metastatic Colorectal Cancer: a Meta-analysis.

Curr Treat Options Oncol 2018 Nov 27;19(12):77. Epub 2018 Nov 27.

Medical Oncology Department, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital of Sun Yat-Sen University, No. 26 Yuan Cun Er Heng Road, Guangzhou, 510655, China.

Opinion Statement: Nowadays, systemic chemotherapy with intravenous (IV) 5-fluorouracil (5-FU) remains the most commonly prescribed treatment for metastatic colorectal cancers (CRC), in combination with other cytotoxic drugs. 5-FU can be administered through a bolus injection or continuous infusion (cIV), with the latter becoming the preferred administration method and standard of care in recent years. Oral fluoropyrimidines were developed to overcome challenges associated with the IV administration of 5-FU, among which capecitabine has become the most widely used one. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-018-0597-yDOI Listing
November 2018
13 Reads

Proton Therapy in Non-small Cell Lung Cancer.

Curr Treat Options Oncol 2018 Nov 27;19(12):76. Epub 2018 Nov 27.

Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.

Opinion Statement: Non-small cell lung cancer (NSCLC) accounts for 85% of new lung cancer cases and has 5-year survival rates ranging from 92% in early-stage disease to as low as 13% in locally advanced cases. Radiation therapy is a key component in the treatment repertoire for NSCLC, where it is currently used alone or in combinations with chemotherapy and surgery. Despite the broad use of modern photon radiation techniques, as many as 25% of patients experience isolated locoregional recurrences, and toxicity has been proven to be a limiting factor in many cases. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-018-0588-z
Publisher Site
http://dx.doi.org/10.1007/s11864-018-0588-zDOI Listing
November 2018
14 Reads

Radical Trachelectomy for Early Stage Cervical Cancer.

Curr Treat Options Oncol 2018 Nov 19;19(12):75. Epub 2018 Nov 19.

Instituto Gyneco-Oncólogico, 252 San Jorge St, San Juan, PR, 00914, USA.

Opinion Statement: In patients with early-stage cervical cancer, radical hysterectomy and pelvic lymphadenectomy is the gold standard. However, this disease commonly affects women of childbearing age; thus an option to spare fertility is ideal. This option came to fruition in the early 90s when the Dargent procedure or radical trachelectomy was first reported. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-018-0591-4DOI Listing
November 2018
2 Reads

Review of Immune Therapies Targeting Ovarian Cancer.

Curr Treat Options Oncol 2018 Nov 14;19(12):74. Epub 2018 Nov 14.

Division of Gynecologic Oncology, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland-Baltimore, 22 S. Greene Street S3AX31, Baltimore, MD, 21201, USA.

Opinion Statement: The rise of immunotherapy is the greatest advance in oncology to occur over the last several years, but applications in gynecologic malignancies lag behind other tumors. The term "immunotherapy" envelops monoclonal antibodies as receptor mediators, including immune checkpoint inhibitors (ICPI), cancer vaccines, and adoptive immunotherapies alone or in combination with other therapeutic approaches. The purpose of this review is to summarize the status of immunotherapy trials in ovarian cancer and to specifically highlight data published in the last 1-2 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-018-0584-3DOI Listing
November 2018
6 Reads

Novel Surgical Strategies in the Treatment of Gynecological Malignancies.

Curr Treat Options Oncol 2018 Nov 9;19(12):73. Epub 2018 Nov 9.

Department of Surgical Oncology, Institut Claudius Regaud-Institut Universitaire du Cancer de Toulouse (IUCT)-Oncopole, 1 avenue Irène Joliot-Curie, 31059, Toulouse Cedex 9, France.

Opinion Statement: The main advancement in the surgical treatment of early cervical cancer has been a de-escalation in the radical surgical approach of early stage disease. Similarly, sentinel lymph node detection with cervical tracer injection can be performed alone in microscopic tumors (stage IA) while additional lymphadenectomy is still performed in macroscopic tumors (IB1 and IIA). Parametrial resection has been progressively reduced in tumors less than 2 cm, and simple procedures, conservative (trachelectomy) or not (simple hysterectomy), are currently being evaluated in several phase III trials. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-018-0582-5
Publisher Site
http://dx.doi.org/10.1007/s11864-018-0582-5DOI Listing
November 2018
22 Reads

Radiation-Related Alterations of Taste Function in Patients With Head and Neck Cancer: a Systematic Review.

Curr Treat Options Oncol 2018 Nov 9;19(12):72. Epub 2018 Nov 9.

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1840 Old Spanish Trail, Box 1150, Houston, TX, 77054, USA.

Opinion Statement: Taste sensation is vital for a healthy body as it influences our food intake, acts as a defense mechanism and elicits pleasure. Majority of the head and neck cancer (HNC) patients undergoing radiotherapy suffer from altered taste function and often complain of inability to taste their food, reduced food intake, and weakness. However, there are not many studies conducted to assess this commonly reported side effect. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-018-0580-7
Publisher Site
http://dx.doi.org/10.1007/s11864-018-0580-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244914PMC
November 2018
11 Reads